Avivagen Inc. is a Canadian life sciences company that specializes in developing and commercial-scale manufacturing of OxC-beta™ technology, an innovative approach aimed at improving animal health and supporting reduced reliance on antibiotics in livestock and aquaculture. The company’s core offering, OxC-Beta™ Lys, is a proprietary oxidized beta-carotene feed additive designed to enhance immune response and promote overall animal performance. By harnessing the natural properties of beta-carotene oxidation products, Avivagen seeks to offer a science-based alternative to traditional antibiotic growth promoters.
Since its incorporation in Ontario, Canada, Avivagen has advanced its technology through a series of third-party trials and collaborations with feed producers, academic institutions and contract manufacturers. These joint efforts have generated efficacy data demonstrating improvements in feed conversion ratios, health biomarkers and mortality reduction across poultry, swine and aquaculture species. The company continues to strengthen its regulatory dossier as it pursues approvals in key markets and expands production capacity to meet growing demand for antibiotic-free feed solutions.
Avivagen operates primarily in North America and Southeast Asia, where rising consumer concerns over antibiotic resistance have driven interest in natural feed additives. The company maintains pilot and commercial partnerships in the United States, Canada and China, positioning its OxC-beta™ technology to address both developed and emerging markets. Manufacturing is managed through toll-processing agreements to ensure scalability and cost efficiency, while supply chain logistics are optimized for timely delivery to regional feed integrators and distributors.
The organization is led by a management team with backgrounds in biochemistry, animal nutrition and commercial strategy, supported by an advisory board of industry experts. This leadership directs ongoing research and development, business development and quality assurance efforts, aiming to secure broader market adoption of OxC-beta™ products. Avivagen’s publicly traded status on the OTC Markets under the symbol VIVXF underscores its commitment to transparency and long-term growth in the animal health sector.
AI Generated. May Contain Errors.
